Increase in serum total angiotensin-converting enzyme activity with enalapril therapy in humans: a controlled trial.
1. In a controlled, randomized double-blind trial, 15 patients with essential hypertension were treated with enalapril 5-20 mg/day, or doxazosin 1-8 mg/day, during a 7 week dose titration phase. This was followed by 7 weeks of combined treatment with doxazosin and enalapril. 2. Blood was taken after a 2 week placebo run-in phase, and at 3 and 7 weeks in the single-agent and combined treatment phases, for measurement of plasma renin activity (PRA), plasma angiotensin II (AII), plasma aldosterone and serum free and total angiotensin-converting enzyme (ACE) activities. 3. Doxazosin had no effect on serum free or total ACE activities. 4. Enalapril reduced serum free ACE activity and increased serum total ACE activity, which at 7 weeks was significantly greater than in patients receiving doxazosin. 5. In those patients who received enalapril, 10 mg/day for 3 weeks and then 20 mg/day for 4 weeks (n = 12), with or without doxazosin, mean serum total ACE activity increased by 51%. PRA was also increased in this group, but there were no changes in plasma AII or aldosterone concentrations.
Stokes
G S
GS
Department of Clinical Pharmacology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
Monaghan
J C
JC
Marwood
J F
JF
Okoro
E O
EO
Johnston
H
H
D004311:Double-Blind Method; D017292:Doxazosin; D004334:Drug Administration Schedule; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000097:blood*; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects
D004656:Enalapril; D007703:Peptidyl-Dipeptidase A; D017292:Doxazosin; D011224:Prazosin